Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
Purity:
98.40%
CAS Number:
[1610833-03-8]
Target:
Others
T77455
* VAT and and shipping costs not included. Errors and price changes excepted